Blankinship & Foster, LLC Summit Therapeutics Inc. Transaction History
Blankinship & Foster, LLC
- $388 Million
- Q2 2024
A detailed history of Blankinship & Foster, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Blankinship & Foster, LLC holds 12,777 shares of SMMT stock, worth $260,523. This represents 0.03% of its overall portfolio holdings.
Number of Shares
12,777
Previous 12,777
-0.0%
Holding current value
$260,523
Previous $52,000
90.38%
% of portfolio
0.03%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
147Shares Held
66.2MCall Options Held
1.05MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$474 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$180 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$161 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$84.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$60.4 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.1B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...